Neuronetics and Transformations Care Network Join Forces to Expand Availability of Innovative Depression Treatment

Neuronetics, Inc

MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM), a leading name in the field of non-invasive treatments for mental health conditions, has announced a significant expansion of its commercial partnership with Transformations Care Network (TCN), one of America’s largest mental health care providers. The new agreement designates Neuronetics as the exclusive supplier of transcranial magnetic stimulation (TMS) equipment to TCN.

“We’re glad that NeuroStar TMS is a significant part of TCN’s plan to grow and strengthen mental healthcare in their communities,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics.

With an extensive network of facilities across six states and plans for further expansion, TCN’s five-year exclusive agreement with Neuronetics marks a key step in broadening patient access to innovative NeuroStar TMS treatments. This is particularly important for addressing major depressive disorder (MDD), including treatment-resistant depression (TRD), a condition that often proves challenging due to the complexity and difficulty in achieving remission with conventional treatments.

“Transformations Care Network’s alliance with NeuroStar is more than a milestone; it is a tangible manifestation of our vision to integrate the most advanced treatments in our suite of services,” said Brian Wheelan, Chief Executive Officer at Transformations Care Network.

NeuroStar TMS therapy offers a non-invasive, FDA-cleared treatment that has demonstrated efficacy in cases where traditional pharmacological interventions have failed. By integrating NeuroStar TMS into its array of mental health services, TCN not only elevates the standard of care available to patients but also embodies a forward-thinking approach to mental health treatment.

The initiative signals a commitment to embracing advanced technologies and treatments that can make a meaningful difference in the lives of those affected by some of the most intractable forms of depression. This partnership stands as a testament to the ongoing efforts of both Neuronetics and TCN to push the boundaries of mental health treatment and provide patients with the best possible care.

READ:  Verrica Pharmaceuticals Reports Progress on Molluscum Treatment and Pipeline Development

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.